Stimulator of Interferon Genes (STING) ligands and uses thereof

Patent metadata

Field	Value
Publication number	US-11633473-B2
Application number	US-201816766902-A
Country	US
Kind code	B2
Filing date	Nov 27, 2018
Priority date	Nov 27, 2017
Publication date	Apr 25, 2023
Grant date	Apr 25, 2023

Abstract

Provided herein are Stimulator of Interferon Genes (STING) ligand for use in enhancing immune response and/or as adjuvants in vaccines. In some embodiments, STING ligand is used alone or in combination with Alum in an adjuventation system for early life immunization.

First claim

What is claimed is:

1. A method of inducing an immune response to an antigen in a subject in need thereof, the method comprising administering to the subject an effective amount of an antigen and an effective amount of an adjuvantation system comprising a Stimulator of Interferon Genes (STING) ligand, wherein the subject is a newborn.

2. The method of claim 1 , wherein the STING ligand comprises 2′3′-cGAMP.

3. The method of claim 1 , wherein the adjuvantation system further comprises alum.

4. The method of claim 3 , wherein the STING ligand is adsorbed into the alum.

5. The method of claim 3 , wherein the subject is less than 28 days of age at the time of administration.

6. The method of claim 5 , wherein a second administration occurs when the subject is no more than 6 months of age.

7. The method of claim 5 , wherein the subject is born prematurely, has low birth weight or is immune-compromised.

8. The method of claim 1 , wherein the antigen comprises a protein or polypeptide or a nucleic acid encoding a protein or a polypeptide.

9. The method of claim 1 , wherein the antigen is from a microbial pathogen.

10. The method of claim 1 , wherein the antigen is a cancer-specific antigen.

11. The method of claim 1 , wherein the adjuvantation system enhances the production of antigen-specific antibodies, compared to when the antigen is administered alone.

12. The method of claim 1 , wherein the adjuvantation system enhances the cytokine production of antigen-specific T cells, compared to when the antigen is administered alone.

13. The method of claim 1 , wherein the adjuvantation system polarizes the innate immune response toward T follicular helper (Tfh) cell immunity.

14. The method of claim 1 , wherein the adjuvantation system polarizes the innate immune response toward T helper 1 (Th1) cell immunity.

15. The method of claim 1 , wherein the adjuvantation system prolongs a protective effect in the subject against the antigen, compared to when the antigen is administered alone.

16. The method of claim 1 , wherein the adjuvantation system increases rate of an immune response, compared to when the antigen is administered alone.

17. The method of claim 1 , wherein the antigen produces a same level of immune response against the antigen at a lower dose in the presence of the adjuvantation system, compared to when the antigen is administered alone.

Assignees

• Childrens Medical Center

Inventors

• Levy Ofer
• Dowling David J
• Borriello Francesco
• Pietrasanta Carlo

Classifications

• A61K39/145

  Orthomyxoviridae, e.g. influenza virus · CPC title

• A61K2039/55

  characterised by the host/recipient, e.g. newborn with maternal antibodies · CPC title

• A61K2039/55505

  Inorganic adjuvants · CPC title

• A61K2039/55561

  CpG containing adjuvants; Oligonucleotide containing adjuvants · CPC title

• C12N2760/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title